Details of the Drug

General Information of Drug (ID: DMQLT4N)

• Drug Name: Brimonidine
• Synonyms: brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine

Indication

Disease Entry	ICD 11	Status	REF
Ocular hypertension	9C61.01	Approved	[1], [2]
Glaucoma/ocular hypertension	9C61	Phase 3	[3]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 292.13
  Topological Polar Surface Area (xlogp); 0.6
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 0.417 +/- 0.264 mcgh/L [4]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 46 +/- 62 ng/L [4]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-4 h [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
  Elimination: 10% of drug is excreted from urine in the unchanged form [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [6]
  Metabolism: The drug is metabolized via the hepatic [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.011 micromolar/kg/day [8]
  Water Solubility: The ability of drug to dissolve in water is measured as 1.5 mg/mL [5]
• Chemical Identifiers:
  Formula: C11H10BrN5
  IUPAC Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
  Canonical SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
  InChI: InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
  InChIKey: XYLJNLCSTIOKRM-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2435
  ChEBI ID: CHEBI:3175
  CAS Number: 59803-98-4
  DrugBank ID: DB00484
  TTD ID: D0AE3X

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[9]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Modulator	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Ocular hypertension
• ICD Disease Classification: 9C61.01

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	1.76E-01	-0.06	-0.28

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brimonidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Brimonidine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[29]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Brimonidine and Oliceridine.	Acute pain [MG31]	[30]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[30]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Brimonidine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Brimonidine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Tripelennamine	DMZBU15	Moderate	Additive CNS depression effects by the combination of Brimonidine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Buspirone	DMBS632	Moderate	Additive CNS depression effects by the combination of Brimonidine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[30]
Clorazepate	DMC3JST	Moderate	Additive CNS depression effects by the combination of Brimonidine and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[30]
Methylphenobarbital	DMDSWAG	Moderate	Additive CNS depression effects by the combination of Brimonidine and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[30]
Hydroxyzine	DMF8Y74	Moderate	Additive CNS depression effects by the combination of Brimonidine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[30]
Halazepam	DMPFWO6	Moderate	Additive CNS depression effects by the combination of Brimonidine and Halazepam.	Anxiety disorder [6B00-6B0Z]	[30]
Chlormezanone	DMTWUXR	Moderate	Additive CNS depression effects by the combination of Brimonidine and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[30]
Oxazepam	DMXNZM4	Moderate	Additive CNS depression effects by the combination of Brimonidine and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[30]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Brimonidine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[30]
Linezolid	DMGFPU2	Moderate	Additive hypertensive effects by the combination of Brimonidine and Linezolid.	Bacterial infection [1A00-1C4Z]	[29]
Retigabine	DMGNYIH	Moderate	Additive CNS depression effects by the combination of Brimonidine and Retigabine.	Behcet disease [4A62]	[30]
Lamotrigine	DM8SXYG	Moderate	Additive CNS depression effects by the combination of Brimonidine and Lamotrigine.	Bipolar disorder [6A60]	[30]
Cariprazine	DMJYDVK	Moderate	Additive CNS depression effects by the combination of Brimonidine and Cariprazine.	Bipolar disorder [6A60]	[30]
Diphenoxylate	DMO5SZX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Diphenoxylate.	Bowel habit change [ME05]	[30]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Brimonidine and Loperamide.	Bowel habit change [ME05]	[30]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dihydrocodeine.	Chronic pain [MG30]	[30]
Levetiracetam	DMTGDN8	Moderate	Additive CNS depression effects by the combination of Brimonidine and Levetiracetam.	Chronic pain [MG30]	[30]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Brimonidine and Olopatadine.	Conjunctiva disorder [9A60]	[30]
Azelastine	DMXTMBJ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Azelastine.	Conjunctiva disorder [9A60]	[30]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Brimonidine and Propofol.	Corneal disease [9A76-9A78]	[30]
Thiopental	DMGP8AX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Thiopental.	Corneal disease [9A76-9A78]	[30]
Ketamine	DMT5HA4	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ketamine.	Corneal disease [9A76-9A78]	[30]
Alfentanil	DMVO0UB	Moderate	Additive CNS depression effects by the combination of Brimonidine and Alfentanil.	Corneal disease [9A76-9A78]	[30]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Brimonidine and Remifentanil.	Corneal disease [9A76-9A78]	[30]
Dextromethorphan	DMUDJZM	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dextromethorphan.	Cough [MD12]	[30]
Chlophedianol	DMXGJEI	Moderate	Additive CNS depression effects by the combination of Brimonidine and Chlophedianol.	Cough [MD12]	[30]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ethanol.	Cystitis [GC00]	[30]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Brimonidine and Trimipramine.	Depression [6A70-6A7Z]	[30]
Cyclobenzaprine	DM1YBRM	Moderate	Additive CNS depression effects by the combination of Brimonidine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[30]
Nortriptyline	DM4KDYJ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Nortriptyline.	Depression [6A70-6A7Z]	[30]
Nefazodone	DM4ZS8M	Moderate	Additive CNS depression effects by the combination of Brimonidine and Nefazodone.	Depression [6A70-6A7Z]	[30]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Brimonidine and Selegiline.	Depression [6A70-6A7Z]	[29]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Brimonidine and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
Tranylcypromine	DMGB5RE	Moderate	Additive hypertensive effects by the combination of Brimonidine and Tranylcypromine.	Depression [6A70-6A7Z]	[29]
OPC-34712	DMHG57U	Moderate	Additive CNS depression effects by the combination of Brimonidine and OPC-34712.	Depression [6A70-6A7Z]	[30]
Phenelzine	DMHIDUE	Moderate	Additive hypertensive effects by the combination of Brimonidine and Phenelzine.	Depression [6A70-6A7Z]	[29]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Brimonidine and Clomipramine.	Depression [6A70-6A7Z]	[30]
Trazodone	DMK1GBJ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Trazodone.	Depression [6A70-6A7Z]	[30]
Amoxapine	DMKITQE	Moderate	Additive CNS depression effects by the combination of Brimonidine and Amoxapine.	Depression [6A70-6A7Z]	[30]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Brimonidine and Doxepin.	Depression [6A70-6A7Z]	[30]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Brimonidine and Maprotiline.	Depression [6A70-6A7Z]	[30]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Brimonidine and Esketamine.	Depression [6A70-6A7Z]	[30]
Heroin diacetylmorphine	DMDBWHY	Moderate	Additive CNS depression effects by the combination of Brimonidine and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[30]
Tetrabenazine	DMYWQ0O	Moderate	Additive CNS depression effects by the combination of Brimonidine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[30]
Meclizine	DMS7T13	Moderate	Additive CNS depression effects by the combination of Brimonidine and Meclizine.	Dizziness and giddiness [MB48]	[30]
Diazepam	DM08E9O	Moderate	Additive CNS depression effects by the combination of Brimonidine and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[30]
Zonisamide	DM0DTF7	Moderate	Additive CNS depression effects by the combination of Brimonidine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[30]
Primidone	DM0WX6I	Moderate	Additive CNS depression effects by the combination of Brimonidine and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[30]
Felbamate	DM1V5ZS	Moderate	Additive CNS depression effects by the combination of Brimonidine and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[30]
Oxcarbazepine	DM5PU6O	Moderate	Additive CNS depression effects by the combination of Brimonidine and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[30]
Mephenytoin	DM5UGDK	Moderate	Additive CNS depression effects by the combination of Brimonidine and Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Methsuximide	DM6L5VO	Moderate	Additive CNS depression effects by the combination of Brimonidine and Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[30]
Gabapentin	DM6T924	Moderate	Additive CNS depression effects by the combination of Brimonidine and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Ethosuximide	DMDZ9LT	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ethosuximide.	Epilepsy/seizure [8A61-8A6Z]	[30]
Cenobamate	DMGOVHA	Moderate	Additive CNS depression effects by the combination of Brimonidine and Cenobamate.	Epilepsy/seizure [8A61-8A6Z]	[30]
Tiagabine	DMKSQG0	Moderate	Additive CNS depression effects by the combination of Brimonidine and Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[30]
Stiripentol	DMMSDOY	Moderate	Additive CNS depression effects by the combination of Brimonidine and Stiripentol.	Epilepsy/seizure [8A61-8A6Z]	[30]
Phenacemide	DMOHS9P	Moderate	Additive CNS depression effects by the combination of Brimonidine and Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[30]
Fosphenytoin	DMOX3LB	Moderate	Additive CNS depression effects by the combination of Brimonidine and Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Paramethadione	DMR5ZUP	Moderate	Additive CNS depression effects by the combination of Brimonidine and Paramethadione.	Epilepsy/seizure [8A61-8A6Z]	[30]
Brivaracetam	DMSEPK8	Moderate	Additive CNS depression effects by the combination of Brimonidine and Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[30]
Clonazepam	DMTO13J	Moderate	Additive CNS depression effects by the combination of Brimonidine and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[30]
Rufinamide	DMWE60C	Moderate	Additive CNS depression effects by the combination of Brimonidine and Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[30]
Ethotoin	DMXWOCP	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Phenobarbital	DMXZOCG	Moderate	Additive CNS depression effects by the combination of Brimonidine and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[30]
Vigabatrin	DMYT0OG	Moderate	Additive CNS depression effects by the combination of Brimonidine and Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Carbamazepine	DMZOLBI	Moderate	Additive CNS depression effects by the combination of Brimonidine and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[30]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Brimonidine and Cannabidiol.	Epileptic encephalopathy [8A62]	[30]
Diphenhydramine	DMKQTBA	Moderate	Additive CNS depression effects by the combination of Brimonidine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[30]
Dantrolene	DM1D8XY	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dantrolene.	Fever [MG26]	[30]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Brimonidine and Procarbazine.	Hodgkin lymphoma [2B30]	[29]
Amantadine	DMS3YE9	Moderate	Additive CNS depression effects by the combination of Brimonidine and Amantadine.	Influenza [1E30-1E32]	[30]
Suvorexant	DM0E6S3	Moderate	Additive CNS depression effects by the combination of Brimonidine and Suvorexant.	Insomnia [7A00-7A0Z]	[30]
Amobarbital	DM0GQ8N	Moderate	Additive CNS depression effects by the combination of Brimonidine and Amobarbital.	Insomnia [7A00-7A0Z]	[30]
Ramelteon	DM7IW9J	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ramelteon.	Insomnia [7A00-7A0Z]	[30]
Flurazepam	DMAL4G0	Moderate	Additive CNS depression effects by the combination of Brimonidine and Flurazepam.	Insomnia [7A00-7A0Z]	[30]
Triazolam	DMETYK5	Moderate	Additive CNS depression effects by the combination of Brimonidine and Triazolam.	Insomnia [7A00-7A0Z]	[30]
Zaleplon	DMGFWSM	Moderate	Additive CNS depression effects by the combination of Brimonidine and Zaleplon.	Insomnia [7A00-7A0Z]	[30]
Propiomazine	DMKY8V1	Moderate	Additive CNS depression effects by the combination of Brimonidine and Propiomazine.	Insomnia [7A00-7A0Z]	[30]
Tasimelteon	DMLOQ1V	Moderate	Additive CNS depression effects by the combination of Brimonidine and Tasimelteon.	Insomnia [7A00-7A0Z]	[30]
Paraldehyde	DMOC1BX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Paraldehyde.	Insomnia [7A00-7A0Z]	[30]
ITI-007	DMUQ1DO	Moderate	Additive CNS depression effects by the combination of Brimonidine and ITI-007.	Insomnia [7A00-7A0Z]	[30]
Nabilone	DMVRYT2	Moderate	Additive CNS depression effects by the combination of Brimonidine and Nabilone.	Insomnia [7A00-7A0Z]	[30]
Quazepam	DMY4D87	Moderate	Additive CNS depression effects by the combination of Brimonidine and Quazepam.	Insomnia [7A00-7A0Z]	[30]
Estazolam	DMZGXUM	Moderate	Additive CNS depression effects by the combination of Brimonidine and Estazolam.	Insomnia [7A00-7A0Z]	[30]
Remimazolam	DMLVSYX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[30]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Brimonidine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[30]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Brimonidine and Flibanserin.	Mood disorder [6A60-6E23]	[30]
Dexmedetomidine	DM93L4X	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dexmedetomidine.	Mood/affect symptom [MB24]	[30]
Midazolam	DMXOELT	Moderate	Additive CNS depression effects by the combination of Brimonidine and Midazolam.	Mood/affect symptom [MB24]	[30]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Brimonidine and Thalidomide.	Multiple myeloma [2A83]	[30]
Ozanimod	DMT6AM2	Moderate	Additive hypertensive effects by the combination of Brimonidine and Ozanimod.	Multiple sclerosis [8A40]	[29]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Brimonidine and Phenindamine.	Nasopharyngitis [CA00]	[30]
Dimenhydrinate	DM264B3	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dimenhydrinate.	Nausea/vomiting [MD90]	[30]
Promethazine	DM6I5GR	Moderate	Additive CNS depression effects by the combination of Brimonidine and Promethazine.	Nausea/vomiting [MD90]	[30]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Brimonidine and Cyclizine.	Nausea/vomiting [MD90]	[30]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Brimonidine and Metoclopramide.	Nausea/vomiting [MD90]	[30]
E-2007	DMJDYNQ	Moderate	Additive CNS depression effects by the combination of Brimonidine and E-2007.	Neuropathy [8C0Z]	[30]
Sibutramine	DMFJTDI	Moderate	Additive CNS depression effects by the combination of Brimonidine and Sibutramine.	Obesity [5B80-5B81]	[30]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Brimonidine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[30]
Lofexidine	DM1WXA6	Moderate	Additive CNS depression effects by the combination of Brimonidine and Lofexidine.	Opioid use disorder [6C43]	[30]
Pentazocine	DM1XBHS	Moderate	Additive CNS depression effects by the combination of Brimonidine and Pentazocine.	Pain [MG30-MG3Z]	[30]
Dextropropoxyphene	DM23HCX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[30]
Butorphanol	DM5KYPJ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Butorphanol.	Pain [MG30-MG3Z]	[30]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Oxymorphone.	Pain [MG30-MG3Z]	[30]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Brimonidine and Levorphanol.	Pain [MG30-MG3Z]	[30]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Brimonidine and Dezocine.	Pain [MG30-MG3Z]	[30]
Flavoxate	DMKV4NL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Flavoxate.	Pain [MG30-MG3Z]	[30]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Brimonidine and Nalbuphine.	Pain [MG30-MG3Z]	[30]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Brimonidine and Buprenorphine.	Pain [MG30-MG3Z]	[30]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Brimonidine and Hydrocodone.	Pain [MG30-MG3Z]	[30]
Ziconotide	DMSLJP4	Moderate	Additive CNS depression effects by the combination of Brimonidine and Ziconotide.	Pain [MG30-MG3Z]	[30]
Oxycodone	DMXLKHV	Moderate	Additive CNS depression effects by the combination of Brimonidine and Oxycodone.	Pain [MG30-MG3Z]	[30]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Brimonidine and Safinamide.	Parkinsonism [8A00]	[29]
Pergolide	DM14MAE	Moderate	Additive CNS depression effects by the combination of Brimonidine and Pergolide.	Parkinsonism [8A00]	[30]
Opicapone	DM1BKA6	Moderate	Additive CNS depression effects by the combination of Brimonidine and Opicapone.	Parkinsonism [8A00]	[30]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Brimonidine and Rasagiline.	Parkinsonism [8A00]	[29]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Brimonidine and Biperiden.	Parkinsonism [8A00]	[30]
Entacapone	DMLBVKQ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Entacapone.	Parkinsonism [8A00]	[30]
Levodopa	DMN3E57	Moderate	Additive CNS depression effects by the combination of Brimonidine and Levodopa.	Parkinsonism [8A00]	[30]
Bromocriptine	DMVE3TK	Moderate	Additive CNS depression effects by the combination of Brimonidine and Bromocriptine.	Parkinsonism [8A00]	[30]
Orphenadrine	DMW542E	Moderate	Additive CNS depression effects by the combination of Brimonidine and Orphenadrine.	Parkinsonism [8A00]	[30]
Apomorphine	DMX38HQ	Moderate	Additive CNS depression effects by the combination of Brimonidine and Apomorphine.	Parkinsonism [8A00]	[30]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[30]
Fluphenazine	DMIT8LX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[30]
Triflupromazine	DMKFQJP	Moderate	Additive CNS depression effects by the combination of Brimonidine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[30]
Neupro	DMHEAB1	Moderate	Additive CNS depression effects by the combination of Brimonidine and Neupro.	Restless legs syndrome [7A80]	[30]
Quetiapine	DM1N62C	Moderate	Additive CNS depression effects by the combination of Brimonidine and Quetiapine.	Schizophrenia [6A20]	[30]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Brimonidine and Mesoridazine.	Schizophrenia [6A20]	[30]
Thioridazine	DM35M8J	Moderate	Additive CNS depression effects by the combination of Brimonidine and Thioridazine.	Schizophrenia [6A20]	[30]
Aripiprazole	DM3NUMH	Moderate	Additive CNS depression effects by the combination of Brimonidine and Aripiprazole.	Schizophrenia [6A20]	[30]
Iloperidone	DM6AUFY	Moderate	Additive CNS depression effects by the combination of Brimonidine and Iloperidone.	Schizophrenia [6A20]	[30]
Paliperidone	DM7NPJS	Moderate	Additive CNS depression effects by the combination of Brimonidine and Paliperidone.	Schizophrenia [6A20]	[30]
Haloperidol	DM96SE0	Moderate	Additive CNS depression effects by the combination of Brimonidine and Haloperidol.	Schizophrenia [6A20]	[30]
Perphenazine	DMA4MRX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Perphenazine.	Schizophrenia [6A20]	[30]
Molindone	DMAH70G	Moderate	Additive CNS depression effects by the combination of Brimonidine and Molindone.	Schizophrenia [6A20]	[30]
Thiothixene	DMDINC4	Moderate	Additive CNS depression effects by the combination of Brimonidine and Thiothixene.	Schizophrenia [6A20]	[30]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Brimonidine and Trifluoperazine.	Schizophrenia [6A20]	[30]
Risperidone	DMN6DXL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Risperidone.	Schizophrenia [6A20]	[30]
Asenapine	DMSQZE2	Moderate	Additive CNS depression effects by the combination of Brimonidine and Asenapine.	Schizophrenia [6A20]	[30]
Pimozide	DMW83TP	Moderate	Additive CNS depression effects by the combination of Brimonidine and Pimozide.	Schizophrenia [6A20]	[30]
Fentanyl	DM8WAHT	Moderate	Additive CNS depression effects by the combination of Brimonidine and Fentanyl.	Sensation disturbance [MB40]	[30]
Sufentanil	DMU7YEL	Moderate	Additive CNS depression effects by the combination of Brimonidine and Sufentanil.	Sensation disturbance [MB40]	[30]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Brimonidine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[30]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Brimonidine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[30]
Carbinoxamine	DMCT31R	Moderate	Additive CNS depression effects by the combination of Brimonidine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[30]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Brimonidine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[30]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Brimonidine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[30]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Brimonidine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[30]
Azatadine	DMZ80SB	Moderate	Additive CNS depression effects by the combination of Brimonidine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[30]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [2] ClinicalTrials.gov (NCT00675207) Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs. U.S. National Institutes of Health.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Cantor LB: The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000 May;1(4):815-34. doi: 10.1517/14656566.1.4.815 .
• [5] BDDCS applied to over 900 drugs
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
• [10] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [11] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [12] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [13] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [14] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [15] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [16] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [17] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [18] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [19] Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.
• [20] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [21] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [22] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [23] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [24] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [25] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [26] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [27] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [28] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [29] Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol 108 (1990): 1264-7. [PMID: 2205182]
• [30] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.